A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer

Leong, Trevor; Everitt, Craig; Yuen, Kally; Condron, Sara; Hui, Andrew; Ngan, Samuel Y; Pitman, Alexander G; Lau, Eddie; MacManus, Michael; Binns, David; Ackerly, Trevor; Hicks, Rodney J.

doi:10.1016/j.radonc.2006.02.014

Cited by 166 publications

(84 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The retention index (RI) represented the percent change of 18 F-FDG uptake and was calculated as follows: RI = ΔSUVmax/SUVmax initial x100%, ΔSUVmax = SUVmax delayed -SUVmax initial and RI >10% was considered as a criterion for the diagnosis of malignancy, a threshold that has been widely used in previous studies (2)(3)(4)(5). In this study, we limited metabolic tumor volume (MTV) by a fixed SUV of 2.5, a threshold that has been widely used for diagnosis in previous studies (6)(7)(8). All the measurements were performed on the combined PET-CT images.…”

Section: F-fdg Pet-ctmentioning

confidence: 99%

Predictive value of 18F-fluorodeoxyglucose positron emission tomography - computed tomography compared to postoperative pathological findings for patients with non-small-cell lung cancer

Xue

Zheng

Guo

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. This study was conducted to investigate the predictive value of 18 F-fluorodeoxyglucose positron emission tomography-computed tomography ( 18 F-FDG PET-CT) in patients with non-small-cell lung cancer (NSCLC), compared to that of postoperative pathological findings, for T and N staging and the associations of the metabolic parameters of the primary tumor with histological type and differentiation. The preoperative contrast-enhanced CT and 18 F-FDG PET-CT and postoperative pathological findings of 112 NSCLC patients treated with lobectomy or pneumonectomy combined with systematic mediastinal lymphadenectomy were retrospectively reviewed. Compared to the postoperative pathological findings, the effect of contrast-enhanced CT and 18 F-FDG PET-CT on T and N staging were evaluated. The metabolic tumor volume (MTV) and maximum standardized uptake value (SUVmax) of the primary tumor were measured. The associations between these metabolic parameters and histological type and differentiation were also evaluated. The differences in the accuracy in overall staging and T staging between PET-CT and contrast-enhanced CT were significant (91.1 vs. 69.6%, P=0.000; and 92.9 vs. 76.8%, P=0.000, respectively). The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of regional lymph node metastasis detection were 91.7, 93.0, 86.5, 95.8 and 92.6%, respectively, with PET-CT; and 71.3, 77.2, 60.6, 84.5 and 75.2%, respectively, with contrast-enhanced CT. The SUVmax , t=4.48, P=0.000) were significantly higher for squamous cell carcinoma (SCC) compared to those for adenocarcinoma (AC). There was a positive correlation between the MTV and SUVmax of the primary tumor (Pearson's r=0.838, P=0.000). Significant differences were observed among differentiation subgroups in the SUVmax and MTV of the primary tumor for both SCC and AC. In conclusion, compared to the postoperative pathological findings, the predictive value of 18 F-FDG PET-CT for T and N staging in NSCLC was higher compared to that of contrast-enhanced CT. The FDG uptake of the primary tumor was associated with histological type and differentiation and the difference was statistically significant. Therefore, the SUVmax and MTV of the primary tumor may be valuable indices to partly predict the histological type and grade of differentiation of NSCLC.

show abstract

Section: F-fdg Pet-ctmentioning

confidence: 99%

Predictive value of 18F-fluorodeoxyglucose positron emission tomography - computed tomography compared to postoperative pathological findings for patients with non-small-cell lung cancer

Xue

Zheng

Guo

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…This is especially important for new treatment techniques such as conformal therapy and intensity-modulated radiation therapy. Recently, a number of studies have shown the potential benefit of incorporating functional information from positron emission tomography (PET) images into the radiotherapy treatment planning (RTP) process [1,2]. The standard imaging technique used in RTP is X-ray CT, as it provides both good anatomical detail for defining the target volumes and the electron density information required for dose calculations.…”

Section: Short Communicationmentioning

confidence: 99%

Personnel radiation dose considerations in the use of an integrated PET–CT scanner for radiotherapy treatment planning

Carson¹,

Young²,

Cosgrove³

et al. 2009

BJR

View full text Add to dashboard Cite

“…The fact that PET imaging is functional rather than structural limits its value in local tumour staging, but numerous studies have shown an effect in the identification of regional and distant disease (Rinne et al, 1998;Dwamena et al, 1999;Gould et al, 2001;Hellwig et al, 2001;Kalff et al, 2002), treatment decisions (MacManus et al, 2001;Spaepen et al, 2001;Blum et al, 2003;Heriot et al, 2004), radiotherapy planning (Haustermans et al, 2002;MacManus and Hicks, 2003;Leong et al, 2006) and in the prediction of response (Di Fabio et al, 2005;Duong et al, 2006).…”

mentioning

confidence: 99%

The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer

et al. 2009

View full text Add to dashboard Cite

Accurate inguinal and pelvic nodal staging in anal cancer is important for the prognosis and planning of radiation fields. There is evidence for the role of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in the staging and management of cancer, with early reports of an increasing role in outcome prognostication in a number of tumours. We aimed to determine the effect of FDG-PET on the nodal staging, radiotherapy planning and prognostication of patients with primary anal cancer. Sixty-one consecutive patients with anal cancer who were referred to a tertiary centre between August 1997 and November 2005 were staged with conventional imaging (CIm) (including computed tomography (CT), magnetic resonance imaging, endoscopic ultrasound and chest X-ray) and by FDG-PET. The stage determined by CIm and the proposed management plan were prospectively recorded and changes in stage and management as a result of FDG-PET assessed. Patients were treated with a uniform radiotherapy technique and dose. The accuracy of changes and prognostication of FDG-PET were validated by subsequent clinical follow-up. Kaplan -Meier survival analysis was used to estimate survival for the whole cohort and by FDG-PET and CIm stage. The tumour-stage group was changed in 23% (14 out of 61) as a result of FDG-PET (15% up-staged, 8% down-staged). Fourteen percent of T1 patients (3 out of 22), 42% of T2 patients (10 out of 24) and 40% of T3 -4 patients (6 out of 15) assessed using CIm, had a change in their nodal or metastatic stage following FDG-PET. Sensitivity for nodal regional disease by FDG-PET and CIm was 89% and 62%, respectively. The staging FDG-PET scan altered management intent in 3% (2 out of 61) and radiotherapy fields in 13% (8 out of 61). The estimated 5-year overall survival (OS) and progression-free survival (PFS) for the cohort were 77.3% (95% confidence interval (CI): 55.3 -90.4%) and 72.2% (95% CI: 51.5 -86.4%), respectively. The estimated 5-year PFS for FDG-PET and CIm staged N2-3 disease was 70% (95% CI: 42.8 -87.9%) and 55.3% (95% CI: 23.3 -83.4%), respectively. FDG-PET shows increased sensitivity over CIm for staging nodal disease in anal cancer and changes treatment intent or radiotherapy prescription in a significant proportion of patients.

show abstract

A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer

Cited by 166 publications

References 21 publications

Predictive value of 18F-fluorodeoxyglucose positron emission tomography - computed tomography compared to postoperative pathological findings for patients with non-small-cell lung cancer

Predictive value of 18F-fluorodeoxyglucose positron emission tomography - computed tomography compared to postoperative pathological findings for patients with non-small-cell lung cancer

Personnel radiation dose considerations in the use of an integrated PET–CT scanner for radiotherapy treatment planning

The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer

Contact Info

Product

Resources

About